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Abstract: Optical coherence tomography (OCT) is a real-time optical imaging technique 
that is similar in principle to ultrasonography, but employs light instead of sound waves 
and allows depth-resolved images with near-microscopic resolution. Endoscopic OCT 
allows the evaluation of broad-field and subsurface areas and can be used ancillary to 
standard endoscopy, narrow band imaging, chromoendoscopy, magnification endoscopy, 
and confocal endomicroscopy. This review article will provide an overview of the clinical 
utility of endoscopic OCT in the gastrointestinal tract and of recent achievements using 
state-of-the-art endoscopic 3D-OCT imaging systems. 
Keywords: optical coherence tomography; optical biopsy; endoscopic imaging;  
Barrett’s esophagus; inflammatory bowel disease 
 
1. Introduction 
Optical coherence tomography (OCT) is an imaging technology that enables micron scale,  
cross-sectional and three-dimensional (3D) imaging of sample microstructure in real time [1–3] and 
can work as an “optical biopsy” tool for biomedical applications; i.e., microstructural information of 
tissue can be obtained in vivo with resolutions approaching that of histopathology on excisional biopsy 
without needing to remove tissue specimens or apply additional contrast agents on the tissue [4–6]. 
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OCT can provide nondestructive profilometry as well as 3D analysis of depth-resolved features. OCT 
is an optical analog of ultrasound B mode imaging, which is performed by measuring the echo time 
delay and intensity of back-reflected or backscattered light. As shown in Figure 1, an optical beam is 
scanned across the sample and echoes of backscattered light are measured as a function of axial range 
(depth) and transverse position. 3D imaging is obtained by performing a two-dimensional scan pattern 
at different transverse positions. Three-dimensional OCT (3D-OCT) enables powerful methods for 
visualizing tissue architecture. 3D-OCT generates comprehensive, volumetric data sets, which can be 
used to construct arbitrary cross-sectional images, projections along arbitrary axes, or 3D renderings 
similar to magnetic resonance imaging (MRI) or computed tomography (CT). 
Figure 1. Optical coherence tomography (OCT) generates cross-sectional and 3D images 
of tissue microstructure by measuring the echo time delay and magnitude of backscattered 
light. Architectural morphology can be imaged in vivo and in real time. 
 
OCT is based on a  technique known as low coherence interferometry, which has been previously 
applied to perform optical ranging measurement [7–9]. OCT imaging is performed using a Michelson 
interferometer with a short coherence length light source as shown in Figure 2. One arm of the 
interferometer contains a scanning system that scans the light beam over the sample (XY scan shown 
in Figure 1) and collects the backscattered light. In most biomedical applications, this is usually a 
microscope for imaging excised tissue specimens or small animals in vivo, or an endoscopic fiber optic 
imaging catheter for imaging inside the body [6]. The scanning system determines the field of view 
(FOV) and the transverse resolution, which defines the scale and detail of en face features that the 
OCT system can reveal. The second arm of the interferometer has a scanning reference path delay that 
is mechanically translated over the desired imaging depth in the traditional time domain OCT  
(TD-OCT) configuration. Optical interference between the light from the sample and reference occurs 
only when the optical delays match to within the coherence length of the light [10,11]. “Coherence” 
refers to a temporal property of the light, which is inversely proportional to its wavelength bandwidth 
and quadratically proportional to its central wavelength. Low coherence interferometry enables the 
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echo delay time and magnitude of backscattered light from internal tissue microstructures to be 
measured with high time resolution and sensitivity. 
Figure 2. OCT uses low coherence interferometry to detect the time delay and magnitude 
of backscattered light. 
 
In the early 2000s, dramatic advances in OCT technology have resulted in imaging speeds 10–200 
times faster and detection sensitivity 10–100 fold greater than standard TD-OCT by using a new OCT 
detection technique known as Fourier domain detection. Measuring backscattered light in the Fourier 
domain [12–15] has enabled real-time 3D-OCT imaging for in vivo biomedical applications. While 
conventional OCT directly measures the interference signal, Fourier domain OCT measures the 
spectrum of the interference signal. The OCT axial scan is then obtained by a pplying Fourier 
transformation on t he detected spectrum [13–15]. This Fourier domain OCT includes two different 
types of techniques, namely spectral/Fourier domain OCT (SD-OCT) and swept source OCT  
(SS-OCT, also known as optical Fourier domain imaging, OFDI). Spectral/Fourier domain detection 
uses a spectrometer with a high speed, line scan camera to measure the spectrum of the OCT 
interference signal. SD-OCT typically operates at 800 nm or 1 µm wavelengths with imaging speed of 
29,000–300,000 lines per second [16–20]. This technology has had a great impact especially on 
ophthalmic OCT imaging because it enables ultrahigh resolutions as well as 3D imaging of retinal 
pathologies in vivo for the first time [21,22]. 
On the other hand, SS-OCT uses a w avelength-swept laser light source and a photodetector to 
measure the interference spectrum [23–26], as shown in Figure 3. SS-OCT enables operation at longer 
wavelengths of 1 µm and 1.3 µm and does not need expensive indium gallium arsenide (InGaAs) 
cameras. Imaging at this wavelength range reduces optical scattering and improves imaging penetration 
depths in the tissues [5]. Advances in wavelength-swept lasers have enabled multi-megaherz high speed 
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OCT imaging [27–31]. This technology is well suited for imaging scattering tissues such as in the 
colon, esophagus, and breast ducts, since scattering significantly increases at shorter wavelengths. 
Figure 3. Swept source OCT enables a 10–200× increase in imaging speed compared to 
time domain OCT. (A) Interferometer with path difference ΔL and swept laser light source. 
(B) Light from the sample (dotted) and reference path (dashed) are time delayed.  
(C) Interference beat signal frequency is proportional to delay. (D) Fourier transform of 
beat signal measures the delay ΔL. 
 
Compared to SD-OCT, SS-OCT can have improved sensitivity because there is no spectrometer 
loss and photodiodes used for detection are more sensitive than cameras [32–34], so structural features 
with lower reflectivity can be revealed from the background of OCT images. SS-OCT can also achieve 
improved system dynamic range because it uses high speed and low-noise photo-detectors and higher 
bit depth data acquisition systems, so more detailed structural features corresponding to different 
reflectivity can be distinguished in the OCT images. Moreover, swept source/Fourier domain detection 
can provide a very large number of axial samples, as determined by the speed of the data acquisition 
systems. More axial samples enable an OCT signal with a higher interference beat signal frequency to 
be acquired correctly, corresponding to the information from the deeper regions. Currently, SS-OCT is 
especially well suited for applications requiring the fastest possible imaging speeds at wavelengths of 
1.3 µm and 1 µm. On the other hand, SD-OCT provides a crucial resolution advantage (<3 µm) using 
light source with broader selection of operation wavelength and bandwidth, as the axial resolution of 
OCT is quadratically proportional to the center wavelength of the light source [16,35,36]. Therefore, 
for applications where slower speeds are acceptable, but axial resolution is of critical importance, such 
as retinal imaging, SD-OCT remains the dominant technology. 
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2. Utility of Endoscopic OCT in the Gastrointestinal Tract 
Gastrointestinal (GI) cancers are estimated to account for more than 290,000 new cases of cancers 
and cause more than 140,000 deaths in the United States in 2014 [37], but are difficult to detect early 
enough to impact on mortality owing to their insidious onset. They often arise in the setting of chronic 
inflammation or injury, and early diagnosis currently depends largely on endoscopic evaluation and 
procurement of tissues for pathological confirmation. 
2.1. Detection of Diseases in the GI Tract 
Esophageal cancer has a five-year survival rate of only 16% [38]. In the past two decades, the 
incidence of esophageal squamous carcinoma has declined in the United States, but the incidence of 
esophageal adenocarcinoma bears the notoriety of having the most rapid rise of all cancers. Barrett’s 
esophagus (BE) is believed to arise from chronic mucosal injury caused by ga stroesophageal reflux 
disorder and to be a precursor of esophageal adenocarcinoma [39]. BE is characterized by the 
replacement of squamous epithelium with columnar epithelium in the esophagus caused by c hronic 
exposure to the acid environment [40]. Neoplastic changes in BE are thought to develop in stages from 
non-dysplastic metaplasia to increasing grades of dysplasia and eventually to adenocarcinoma [41]. 
Thus, early detection and ablation of the preceding dysplasias is a promising strategy for reducing the 
risk of adenocarcinoma [42]. 
Colorectal cancer is another common GI disease with high morbidity and mortality rates. Colorectal 
cancer is the third leading cause of cancer death in the United States, accounting for about 10% of 
cancer death overall [38]. Despite its high incidence, colorectal cancer is one of the most detectable, 
and, if found early, most treatable forms of cancer. Although most colorectal cancers arise from 
adenomatous polyps that are detectable using conventional endoscopy, many flat (non-polypoid) 
lesions are missed during routine examinations [43]. Up to 50% of these more subtle lesions are 
missed by c onventional endoscopy [44]. This is particularly relevant in patients with inflammatory 
bowel diseases (IBDs) such as u lcerative colitis (UC) and Crohn’s disease (CD), where neoplastic 
tissue can be flat rather than polypoid in form and multifocal in distribution thereby evading 
endoscopic detection [45]. As many as 1.4 million individuals in the United States have IBDs [46] and 
are at increased risk for the development of colorectal cancer [47]. 
The current standard procedure to detect dysplasia or early stage cancer is to perform biopsy in the 
identifiably abnormal regions using endoscopy, or random biopsies over a broad area (such as entire 
length of BE or entire length of colon in patients with history of pancolitis) and diagnosis is made 
according to the histology results [48,49]. Besides inadequate sampling, the problem of early detection 
of dysplasias in the gut is exacerbated in the presence of chronic inflammatory conditions such as 
esophagitis and IBD, since early-stage lesions are difficult to distinguish from inflamed GI mucosa by 
the endoscopist. Thus, an imaging modality such as OCT which can provide broad-field, sub-surface, 
and near-microscopic imaging capabilities during endoscopy could help differentiate neoplastic tissue 
from inflamed tissue and help target areas for biopsy or ablation. 
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2.2. Assessment of Endoscopic Therapies for GI Diseases 
Improved endoscopic imaging tools have a uniquely suited role with the advent of endoscopic ablative 
therapies. GI mucosal diseases can be treated using endoscopic mucosal resection (EMR) [50,51]  
or endoscopic ablative therapies, such as argon plasma coagulation (APC) [52], photodynamic therapy 
(PDT) [42], radiofrequency ablation (RFA) [53], and cryospray ablation (CSA) [54]. RFA and  
CSA are recently developed methods that utilize thermal gradients to treat dysplastic or cancerous  
GI lesions. 
RFA uses heat generated by high frequency alternating current to treat the diseased area and has 
been demonstrated as an effective treatment for dysplastic BE. Of 142 patients with high grade 
dysplasia (HGD) undergoing circumferential RFA, Ganz, et al. reported complete response in 
eradicating HGD in 90.2% and complete response eradicating all dysplasias in 80.4% [55].  
Sharma et al. reported 70% and 98% complete response in BE patients at 12 months and 30 months 
follow-up respectively after RFA treatment [56,57]. Pouw et al. reported 98% complete histological 
eradication of all dysplasia and intestinal metaplasia in 44 BE patients treated with RFA [58]. One 
randomized trial using RFA in BE patients with dysplasia has also been published by Shaheen et al. 
and 77.4% complete eradication of intestinal metaplasia over 12 months was reported [53]. 
CSA, on the other hand, uses dispersed liquid nitrogen to rapidly freeze and destroy the diseased 
tissue. CSA has also been shown to be effective in eradicating HGD in the esophagus. Johnston et al. 
reported 78% complete histological eradication of BE in 11 patients using CSA [54]. Greenwald et al. 
reported 94%, 88%, and 53% complete response of the HGD, all dysplasia, and intestinal metaplasia, 
respectively, in a cohort of 77 patients with BE treated by CSA [59]. Shaheen et al. reported 97%, 
87%, and 57% complete eradication of HGD, all dysplasia, and intestinal metaplasia in 98 BE patients 
treated with CSA [60]. 
Several studies indicate that both RFA and CSA allow broad and superficial treatment fields for GI 
diseases [53,54,61,62], but some other studies show that the recurrences of the diseases were observed 
months or years after successful eradication. Vaccaro et al. reported a 25.9% cumulative incident of 
newly detected intestinal metaplasia in one year [63]. Fleischer et al. reported 8% BE recurrence in 50 
patients who had complete eradiation of BE during the five-year follow-up in a prospective multicenter 
trial [64]. There are several possible causes that the recurrence of the GI diseases can occur after the 
complete eradication. One postulate is that, after the ablation therapies, the ablated sites recover with 
neosquamous epithelium covering on t he top. A significant portion (20%–30%) of patients show 
subsquamous intestinal metaplasia (sometimes referred to as “buried glands”, or SSIM) under the 
neosquamous epithelium after the therapeutic treatment based on random biopsies [65,66], which 
could be associated with a future risk of recurrence of BE or progression to adenocarcinoma under the 
neosquamous epithelium [52,67]. Currently, random four-quadrant biopsy is the clinical standard for 
evaluating dysplasia and adenocarcinoma in BE and colorectal cancer patients [68,69]. Due to the 
limitation sampling area (about 1–2 mm2) and sampling depth of biopsy forceps, SSIM was only found 
in 25% of patients before and in 5% of patients after successful RFA treatment [53,60,62,64].  
A technology such as 3D-OCT that can be used for guiding excisional biopsy and providing subsurface 
tissue imaging would significantly reduce sampling errors, improving diagnostic sensitivity, treatment 
follow-up, and outcome. 
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3. Development of Endoscopic OCT  
OCT technology has been successfully applied to numerous biomedical fields including 
ophthalmology [70], cardiology [71], gastroenterology [72], urology [73], and gynecology [74]. 
Applications for an ultrahigh speed 3D-OCT imaging are particularly promising in gastroenterology. 
OCT can be readily integrated with a wide range of imaging devices such as fiber optic catheters and 
endoscopes to enable imaging inside the body [6]. The first demonstration of in vivo endoscopic OCT 
was performed by T earney et al. [6]. This study demonstrated high speed OCT imaging of the 
gastrointestinal and pulmonary tracts in the rabbit using a 1mm diameter fiber optic catheter.  
The earlier development of endoscopic OCT technology can be found in the detailed review by 
Yaqoob et al. [75]. 
3.1. Earlier Clinical Studies Using Endoscopic OCT 
Endoscopic OCT imaging of the human gastrointestinal (GI) tract has been investigated by several 
groups and studies have been performed in the esophagus and stomach [72,76–83], small and large 
intestine [77,79,84–88], and bile duct [89,90]. Barrett’s esophagus was clearly differentiated from  
non-neoplastic tissues. OCT has been demonstrated to detect specialized intestinal metaplasia in BE 
patients [91,92] and transmural inflammation in IBD patients [85]. OCT has also been investigated for 
differentiating hyperplastic from adenomatous polyps in the colon [86]. Recent endoscopic OCT 
studies have shown promise for detection of HGD in BE. Evans, et al. reported a sensitivity of 83% 
and a specificity of 75% for detecting HGD and intramucosal carcinoma with blinded scoring of OCT 
images from 55 patients [93]. Isenberg et al. reported a sensitivity of 68% and a specificity of 82%, 
with an accuracy of 78% for the detection of dysplasia from 33 pa tients with BE [94]. Using  
computer-aided tissue classification techniques applied to OCT images, Qi et al. reported a sensitivity 
of 82% and a specificity of 74% for identifying dysplasia in 13 patients [95]. 
3.2. Important Advancement Using High Speed Fourier Domain OCT 
With the development of Fourier domain OCT technologies, endoscopic OCT imaging has recently 
been demonstrated with much higher imaging speed and better resolution. Ultrahigh resolution 
spectral/Fourier domain endoscopic OCT with 2.4 µm axial resolution using a Ti:Sapphire laser with 
20 kHz axial scan rates was demonstrated in the mouse colon [96]. Using swept source/Fourier domain 
technologies, in vivo 3D-OCT volumetric imaging of the porcine esophagus and artery has been 
demonstrated at 10 kHz and 54 kHz axial scan rates, respectively [97,98]. Using FDML technologies, 
Prof. Fujimoto’ s group at MIT achieved record axial scan rates of 100–500 kHz and demonstrated  
in vivo endoscopic 3D-OCT imaging in the rabbit and human GI tracts with axial resolution of  
7–20 µm [29,99]. Suter et al. demonstrated comprehensive volumetric endomicroscopy of the human 
distal esophagus using 3D-OCT and a balloon-centering imaging catheter, providing a wealth of 
detailed information about different structural features of the normal esophagus, esophageal 
specialized intestinal metaplasia, high grade dysplasia, and intramucosal carcinoma [100]. These 
endoscopic studies demonstrate that OCT imaging can be readily integrated with endoscopic 
procedures and potentially provides valuable diagnostic information. There are still very few clinical 
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studies using endoscopic OCT in the GI tract that provide significant solutions to certain clinical 
problems, and only recently were such instruments commercially available, so currently OCT remains 
largely an investigational tool not accepted as a standard imaging modality for most GI clinics. 
3.3. Comparison between Different Endoscopic Imaging Technologies 
Several advanced imaging technologies have been developed to increase the yield of the endoscopy 
surveillance. Chromoendoscopy with topically applied dyes such as methylene blue or indigo carmine 
over the regions of interest facilitates the detection of nonpolypoid lesions based on the enhancement 
of surface morphology [101–104], but the main limitations of chromoendoscopy are the requirements 
of high quality bowel preparations for standard colon screening, large volume of dye, time required for 
dye uptake, and need for copious flushing [105,106]. Virtual chromoendoscopy such as narrow-band 
imaging (NBI), where light of specific blue or green wavelengths is used, can enhance the detail of 
certain aspects of the tissue surface such as blood vessels without any application of dye [107,108]. 
Although chromoendoscopy and NBI are able to enhance the tissue contrast and distinguish lesions 
from normal tissue, the optical resolution of these methods with standard endoscope is not sufficient to 
distinguish dysplasia from non-dysplastic tissues. Recent studies show that these ancillary imaging 
modalities do not enhance detection sensitivity or specificity over standard white light endoscopy in 
general clinical practice [109,110]. In conjunction with high-magnification endoscope, which has not 
yet been widely available in the United States, it is possible to use chromoendoscopy or NBI to 
visualize different pit patterns of the lesion and detect dysplasia in the colon based on the Kudo 
classification [111] and in the esophagus based on the Paris classification [112,113]. Confocal laser 
endomicroscopy (CLE) is another emerging technology that allows microscopic examination of the GI 
tract and has been demonstrated having high sensitivity and specificity in differentiating neoplasia in 
both esophagus and colon [114–119]. CLE requires the use of exogenous contrast agents such as 
intravenous fluorescein and topical acriflavine (not approved for human use in the United States), so 
the time for imaging is limited due to excretion of fluorescein [120,121]. The high magnification of 
CLE also limits its field of view (FOV) and imaging depth, making it impractical to survey large areas 
for possible malignancy or to detect important features in the deeper tissue regions. Table 1 shows a 
comparison of features between these endoscopic imaging technologies. Among these imaging 
modalities, endoscopic OCT can uniquely provide volumetric structural information in the GI tract and 
is well-suited for early GI cancer detection including screening and surveillance. Recently, several “red 
flag” techniques, such as the application of fluorescence-labeled peptides that can specifically bind the 
dysplastic regions [122–125] and angle resolved low coherence interferometry (a/LCI) that uses  
depth-resolved nuclear morphology measurements to detect dysplasia [126–129], also showed 
promising results in identifying dysplastic tissue over a large field in the GI tract. These techniques, 
used solely or in conjunction with OCT, can potentially be very powerful once they are validated with 
large clinical studies in the future. 
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Table 1. Comparison of endoscopic imaging modalities. 




Ultrasound 1–10 cm 50 µm 
Broad field  
Standard for staging tumors despite 
improvements in CT and MR 
Location of neoplasia  
Low resolution 
Chromoendoscopy N/A N/A 
Enhanced endoscopic imaging 
contrast 
Superficial imaging  
Large volume dye required 
NBI N/A N/A 
Enhanced endoscopic imaging 
contrast  
No contrast agent required 
Superficial imaging 
CLE <250 µm 1–5 µm 
Cellular resolution  
Point and view 
Limited imaging depth  
Limited field of view  
IV contrast required 
LCI 200–300 µm N/A 
Assessment of nuclear size  
Red flag technology  
No contrast agent required 
Limited detection depth 
OCT 3 mm 5–30 µm 
No contrast agent required  
3D visualization of tissue structure 
Can’t image fluorescence  
3D presently not real-time 
3.4. Imaging Catheter Designs Using Different Scanning Mechanism 
Generally speaking, there are two main categories of scanning methods used in imaging catheters: 
proximal actuation and distal actuation. The imaging catheter with proximal actuation usually contains 
actuators in the patient interface unit (PIU) outside of the human body and far away from the tissue. 
The actuation is usually transferred to the distal end of the imaging catheter via a torque coil or a guide 
wire. Fast axis scanning can be done using high speed rotary or push-pull methods. To acquire 
volumetric OCT data set, slow axis scanning is also required. High speed rotary plus slower pulling 
back of the probe is the most common method to acquire 3D OCT data sets [97,98,100,130–133]. 
On the other hand, distal actuation uses an actuator placed at the distal end of the imaging catheter. 
Hence, the actuator must be made as small as possible to go t hrough the working channel of an 
endoscope or used alongside the endoscope without increasing the overall size too much. There are 
several miniaturized actuators used in distal actuation probes such as piezoelectric transducer (PZT) 
based devices [134–136] and microelectromechanical system (MEMS) based devices [137]. 
Miniaturized actuators can achieve either one-dimensional (1D) or two-dimensional (2D) scanning. 
The actuators are usually controlled electronically and are very close to the imaging surface, so 
electrical isolation is important in these imaging catheters. Figure 4 shows schematics of these 
different scanning methods, including: (1) proximally rotary (short working distance) side imaging,  
(2) proximally rotary balloon (long working distance) imaging, (3) raster scan side imaging, (4) raster 
forward imaging, and (5) spiral forward imaging. 
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Figure 4. Schematics of different scanning methods. (A) Standard rotary scan with pull 
back. (B) Rotary scan with balloon and pull back. (C) Raster scan perpendicular to axis 
with rotation and pull back. (D) Spiral scan. (E) Micromotor rotary scan with pullback.  
(F) Front cross-sectional view of the imaging catheter in the lumen for scanning method 
(A), (C) and (E). (G) Front cross-sectional view of the imaging catheter in the lumen for 
scanning method (B). (H) Front cross-sectional view of the imaging catheter in the lumen 
for scanning method (E) and (D). Black arrow: fast scan. Yellow arrow: slow scan. 
 
3.4.1. Proximal Rotary Side Imaging 
This is the scanning method used in most of the studies conducted with endoscopic OCT imaging, 
which was first developed by our group at MIT in 1996 [130], as shown in Figure 4A. Rotation is 
produced by a high speed motor and transferred to the distal end of the imaging probe via a torque coil. 
Slow scan is performed by slowly pulling back the whole probe to achieve 3D data acquisition. This 
design requires a fiber optic rotary joint so the imaging catheter can continuously rotate in one 
direction. The rotary joint typically has maximum rotary speed of 2000–10,000 revolutions per 
minutes (rpm), corresponding to 33–166 revolutions per second, so the frame rate limit of this method 
is around 150 frames per second (fps). Since the light is always on a xis in the optics, the effect of 
spherical aberration effect (off axis light is focused at different focal plane) is small. Therefore, this 
method is easier for optical design and the beam profile is not distorted due to scanning. Moreover, the 
distal end can be made very small and the rigid length can be short with the simple optic design. 
Typically the outer diameter (OD) of entire probe including sheath can be thinner than 2 mm and the 
rigid length can be less than 2 cm, allowing passage through the accessory channel of most standard 
endoscopes. This proximal rotary method requires the rotation of the whole imaging catheter during 
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the imaging, so the scanning may be hindered by t he bending of the imaging catheter, resulting  
in non-uniform rotation of the distal imaging optics and limiting the image quality even if the 
transverse optical resolution is high. The scanning speed can be limited because the torque coil can 
vibrate when operated at rotary speed higher than a few thousand revolutions per minute (rpm). The 
field of view (FOV) is also limited by t he size of the catheters due to the necessity of keeping the 
catheter close to the tissue surface. For example, for an imaging catheter of 2.5 mm OD, the scanning 
range provided by the catheter is about 8 mm, which is roughly 1/10 of the average circumference of 
adults’ esophagus. Hence, this type of catheter is suitable for applications that focus on relatively small 
regions of interest in the GI tract. 
3.4.2. Proximal Rotary Balloon Imaging 
In order to reduce the environmental instability of the high speed rotary probe, balloon probes were 
adopted to stabilize the probe in the human body, especially for studies in the GI tract [100], as shown 
in Figure 4B. With the balloon design, it is easier to image the entire circumference of the esophageal 
lumen around the imaging catheter and co-register the imaging locations at different time points. The 
balloon increases the working distance (~1 cm) from the optics to the lumen and increases the size of 
the probe, but keeps the spot size on the imaging plane small enough to maintain reasonable transverse 
resolution. With the longer working distance, the aberration of the focal spot caused by any curved 
interface in the catheter is more severe compared to the non-balloon design, so additional corrective 
optical designs are required. Commercial endoscopic OCT instruments such as the NvisionVLE imaging 
system (NinePoint Medical) have recently been introduced which use balloon imaging catheters. 
For single balloon designs, the balloon exerts pressure to the surrounding tissue and may deform the 
tissue structure such as flattening potential cystic structures and compressing the thickness of layers 
(epithelium, lamina propria, muscularis mucosa, etc.) [100]. A double balloon design, which places the 
imaging probe between the two balloons, can solve the deformation issue, but the imaging location in 
the human body will be limited [133]. For example, a double balloon catheter may not be appropriate 
at the gastroesophageal junction (GEJ) because the distal balloon would be in the stomach and cannot 
stabilize the imaging catheter. One general disadvantage of the balloon design is that the probe might 
not always be at the central position of the balloon, so some part of the tissue can be out of the imaging 
range, even if the probe is well stabilized in the lumen. 
3.4.3. Raster Scan Side Imaging 
Proximally actuated imaging catheters generally have the problem that the scanning is not uniform, 
particularly with increased resistance on the torque coil from external compression or bending during 
endoscope articulation. The scanning speed is also limited because the torque cable tends to vibrate 
when operated at rotary speeds higher than a f ew thousand revolutions per minute. This limits the 
ability to obtain detailed structural information and smaller features due to the heartbeat or breathing 
induced motion artifact and lack of registration between sequential images in the pullback. Hence, 
distally actuated scanning probes are preferable for visualizing small features of the tissue. One method 
used for distal actuation involves sweeping the fiber tip at the distal end of the imaging catheter either by 
a PZT or electromagnet actuators to achieve raster scanning [29]. The beam from the fiber tip is then 
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focused by a lens and can be deflected by a prism or mirror. The scanning speed of PZT based benders 
can easily achieve over 1 kHz if the total length of the actuator is short, while the scanning range is 
limited because the scanning range is proportional to the square of the length of actuator [29]. 
An important issue for the scan is the imaging plane distortion caused by the aberration of the lens 
and sheath when the light is scanned away from the optical axis. A compound lens or GRIN lens is 
preferable because it can correct the aberration caused by a single lens [138]. Also, the distortion by 
the curvature of sheath can affect the beam quality while scanning to off axis position. Raster scanning 
perpendicular to the imaging catheter (Figure 4C) has high aberration because the beam is incident 
with a large angle on the curved surface of the probe sheath. 
3.4.4. Spiral Scan Forward Imaging 
Forward imaging using quadruple PZT tubes was demonstrated several years ago [134] as a method 
for small diameter endoscopic imaging and is also a feasible way to acquire endoscopic  
OCT images [135]. As Figure 4F shows, the fiber goes through the PZT tube and can be actuated  
two-dimensionally. By applying amplitude-varying sinusoidal waves with 90° phase difference to the 
two pairs of the electrodes, the fiber tip can be actuated in a spiral pattern and obtain 3D OCT data. 
Since both axes are actuated distally, the scan can be controlled precisely so this scanning mechanism 
is particularly suitable for the high magnification, small field imaging, such as o ptical coherence 
microscopy (OCM) and multi-photon microscopy (MPM). Recently, a new method which drives two 
scanning directions with slightly different frequencies has been described [139]. The resulting 
scanning pattern is a Lissajou pattern with the frame rate of the difference of the two driving 
frequencies. These methods eliminate the need for an additional slow scan, so the probe design can be 
less complex and its size can be smaller than the raster scanning probe. 
However, these scanning methods require very precise mapping of the pixels during the scan. The 
scanning density of the spiral and Lissajou patterns are also non-uniform. Another issue for the 
scanning method is that the fiber tip is driven with frequencies close to its resonance. Any environmental 
perturbation or impact that contains the frequency components close to the resonance frequency of the 
fiber while imaging could couple into the motion of the fiber tip and disrupt the scanning pattern and 
pixel mapping. This is a common problem for raster, spiral, and Lissajou methods because they both 
vibrate the fiber with frequency close to resonance. 
Table 2 summarizes and compares these scanning methods. Depending on the application, a 
specific scanning mechanism with suitable parameters of scanning range, scanning speed, and number 
of pixels in a frame can be used. In addition to the above mentioned scanning mechanisms, imaging 
using distal rotary scanning can be achieved with advances in micromotor technology, which can 
provide large scanning areas while maintaining high speed and uniform rotation. Micromotor catheters  
for ultrahigh resolution in vivo OCT imaging were demonstrated in 2004 for imaging at 2 f ps with 
1000 axial scans per frame [140,141]. Micromotor catheters have been used in upper airway [142]  
and intravascular imaging [143]. Recently, several research groups have demonstrated ultrahigh  
speed endoscopic OCT imaging with imaging speed ranging from 52 to 3200 fps in ex vivo  
specimens [144,145], and 400 fps in the rabbit in vivo [146]. 
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Table 2. Comparison between different scanning mechanisms. 
Scanning Mechanisms Advantage Disadvantage 
Proximally rotary 
Simple optical design  
Small  
No aberration  
Moderate scanning range (1–4 cm2)  
Water can be used to reduce 
reflections/aberration 
Rotary non-uniformity  
Pull back non-uniformity  
Unstable slow scan 
Rotary with single balloon 
Simple optical design  
Small  
More stable for slow scan  
Large scanning range (>30 cm2)  
Cover the whole lumen circumference  
Water can be used to reduce 
reflections/aberration 
Rotary non-uniformity  
Deformation of tissue  
Probe off-centered  
Aberration from sheath 
Rotary with double balloon 
Simple optical design  
Small  
More stable for slow scan  
No tissue deformation  
Large scanning range (>30 cm2)  
Cover the whole lumen circumference  
Water can be used to reduce 
reflections/aberration 
Requires balloon and inflation  
Rotary non-uniformity  
Probe off-centered  
Aberration from sheath  
Imaging location limited 
Raster scan side (perpendicular) 
Higher scanning speed  
Moderate scanning range  
No fast scan non-uniformity 
Image area is long strip  
Larger probe  
Sinusoidal wave correction  
Sensitive to perturbation  
Aberration from scanning at high 
angle to sheath  
Water cannot be used 
Spiral/Lissajou forward scan 
Small  
Simple design  
No fast scan non-uniformity  
Simultaneous 2D scan 
Limited imaging range  
Scanning pattern correction  
Sensitive to perturbation  
Slower scanning speed 
Micromotor 
Highest scanning speed  
No fast scan non-uniformity  
Large scanning range  
Could incorporate with other design 
Proximal pullback required  
Field of view blocked by electric 
cables 
For all the catheter designs, a m ajor practical issue that needs to be considered is the overall 
catheter dimensions, including the outer diameter and the rigid length. These two dimensions 
determine whether an imaging catheter can go through the working channel of the endoscope. The 
typical diameter of the endoscope working channel is between 2.8 and 3.7 mm. Although there are 
some endoscopes with larger working channels (>5 mm diameter), the ~30 degree turn in the insertion 
port of the working channel still limits the diameter of the imaging catheter that can go through the 
channel. Hence, if the imaging catheter needs to go t hrough the working channel of conventional 
Diagnostics 2014, 4 70 
 
 
endoscope, the preferable catheter diameter should be less than 2.5 mm and rigid length less than  
25 mm. This limits the components, including optics and actuators, which can be used to develop the 
imaging catheters. For most of the proximal actuated imaging catheter, these dimension requirements 
are easy to meet because there is no scanning part in the distal end. The other insertion method is the 
“overtube” configuration. Rather than going through the working channel of the endoscope, the 
imaging catheter is attached outside of the endoscope tip. This allows the imaging catheter to be made 
in a larger size and with more component options, which helps to achieve better imaging resolution 
and more stable scanning. However, the overall diameter of the imaging catheter should not be larger 
than 5 mm. Otherwise, it is very difficult to insert the endoscope into the human body with the catheter 
attached. To date, there is no endoscopic OCT study that uses the overtube configuration. 
4. Recent Achievements of Endoscopic OCT in Clinical Gastroenterology 
Endoscopic 3D-OCT imaging has been performed extensively on pa tients with BE or IBD, and 
several case reports and clinical studies have been published recently. This section will provide a brief 
overview of representative studies conducted by different groups using state-of-the-art endoscopic 
OCT system in conjunction with the white light endoscopy, which indicate the unique utility of 
endoscopic OCT in clinical gastroenterology. 
4.1. Laser Marking and OCT Guided Biopsy 
The gold standard method to detect dysplasia and intramucosal carcinoma in Barrett’s patients is to 
perform random, 4-quadrant endoscopic biopsy of the involved esophageal segment. Due to the limited 
overall coverage of random biopsy procedure over the involved tissue, this procedure can lead to a 
high sampling error for detecting malignancy [147]. Endoscopic OCT can provide cross-sectional 
images of the esophagus with a resolution of about 5–30 µm and can accurately detect various 
esophageal pathologies [92–94]. Previously, OCT was able to image only small areas of the esophagus 
at a time owing to limitations of image acquisition speed and catheter scanning mechanism. By using a 
balloon-based catheter that extends the working distance of the OCT imaging and a spiral scan,  
3D-OCT covers a much larger area on a single sweep and enables comprehensive microscopy in the 
distal esophagus within minutes [98,100]. The ability to image the entire esophagus at microscopic 
resolution makes OCT particularly suited for guiding biopsies. Suter et al. developed an OCT imaging 
system that allows superficial and readily visible laser markings on the mucosa corresponding  
to regions of interest on the images to guide biopsies and ablative therapies immediately following 
imaging [83]. 
Figure 5 outlines the steps for directed biopsies using the laser-marking OCT, as validated in a 
recent study using swine. In the study, the balloon catheter was placed in the esophagus alongside the 
endoscope and after positioning, the endoscope was removed and the balloon was inflated. The balloon 
catheter dilated the esophagus and stabilized the imaging probe with respect to the esophageal wall. 
After the laser marking, the endoscope was reintroduced to evaluate the visibility of the laser-marked 
sites. The feasibility of the OCT-guided laser marking was evaluated by determining the optimal laser 
parameters, testing the accuracy of the laser marking process, evaluating the endoscopic visibility of 
the laser marks, and assessing the amount of mucosal damage produced by the laser. 
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Figure 5. Guided biopsy with the use of laser marking and endoscopic OCT imaging.  
(A) volumetric OCT imaging of the region of interest in the esophagus; (B) assessment and 
interpretation of the volumetric data set; (C) selection of point of interest; (D) laser 
marking at corresponding sites on the luminal wall; and (E) endoscopic biopsy at the 
marked sites for histopathologic analysis. Originally published in [83]. 
 
This study showed that all of the laser-induced marks were visible by endoscopy and 97% of the 
target locations were successfully marked. Laser marking in conjunction with OCT imaging was 
demonstrated to be effective for guiding endoscopic biopsy, could potentially enhance the diagnostic 
yield of current endoscopic surveillance protocols, and may provide assistance during other 
interventional treatments such as identifying margins for EMR, as well as with co-registration of the 
endoscopic images and histology. Combined with the laser marking technology, the real-time imaging 
capability of endoscopic OCT is extended to actively mark down the points of interest accurately and 
can be used to guide biopsy in vivo. 
4.2. Cancer Classification 
The use of endoscopic resection (ER) is limited to carcinoma invading the lamina propria  
layer according to the current esophageal cancer management guidelines [148], and surgery or 
chemoradiotherapy is performed for tumor invasion to the muscularis mucosa or deeper layer. 
Endoscopic ultrasound (EUS) has been suggested as a useful method for the evaluation and staging of 
tumor infiltration in superficial esophageal squamous cell carcinomas (SESCCs) [149], but the 
accuracy of EUS is not sufficient due to the poor resolution [84]. Endoscopic OCT is analogous to  
B-mode ultrasound, but can produce higher-resolution cross-sectional images of tissue in real time 
because it uses infrared light that has much shorter wavelength compared to ultrasound. This results in 
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approximately 10-fold better axial resolution images that can identify tissue microstructures, such as 
layered structure in the mucosa and glandular structures [94], and may allow more accurate diagnostic 
assessment of tumor invasion in SESCCs. In normal pig esophagus, the layered structure observed in 
OCT images was demonstrated to correspond to histological structures [150], namely squamous 
epithelium (EP), lamina propria (LP), muscularis mucosa (MM), submucosa (SM), and muscularis 
propria (MP). Hatta et al. performed a clinical study to establish image-based criteria for staging tumor 
infiltration in SESCCs and to evaluate the accuracy of these criteria [151]. In a single center, 
prospective two-phase study, 66 patients with SESCC were enrolled to participate. Using a prototype 
OCT system developed by Lightlab Imaging, Inc. (Westford, MA, USA) and HOYA (Tokyo, Japan), 
35 OCT images from 16 patients were evaluated in the first phase of the study to establish the OCT 
image criteria of three categories (Figure 6) based on SESCC involvement of the layers. In the second 
phase of the study, 109 images from 46 s ubsequent consecutive patients were used for prospective 
evaluation of the criteria. The OCT images were reviewed and staging was assessed by one 
experienced gastroenterologist blinded to endoscopic evaluation and other clinical information. The 
accuracy of the OCT criteria was determined by comparing the OCT-based staging results with the 
histological evaluation of the resected specimens. The overall accuracy to identify the depth of the 
cancer invasion based on OCT images was 92.7% (101/109), and the accuracy of cancers that reach 
EP/LP, MM, and SM layers was 94.7% (74/78), 85.0% (17/20), and 90.9% (10/11), respectively. The 
OCT imaging criteria developed for staging tumor invasion was demonstrated to accurately stage 
SESCCs and can be useful in determining endoscopic resectability. However, this study also pointed 
out the limitations of OCT, including the limited image penetration, inability to discern cancer  
cell invasion and inflammatory cell infiltration, and inability to discriminate the cancer within  
EP layer alone from normal esophageal tissue. These limitations may be overcome by further 
development of OCT technology to provide deeper image penetration, higher resolution as with the 
ultrahigh-resolution OCT [152], and functional imaging as with Doppler OCT [153]. 
Figure 6. OCT imaging criteria for the staging of SESCC. The dark gray area indicates 
tumor. Originally published in [151]. 
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4.3. Investigation of Subsquamous Intestinal Metaplasia  
Subsquamous intestinal metaplasia (SSIM), also known as buried glands, is usually underappreciated 
with current surveillance protocols using standard white light endoscopy [154]. Endoscopic 3D-OCT 
imaging uniquely enables depth-resolved imaging of a broad area with near-microscope resolution and 
can be used for identifying and characterizing SSIM before and after ablative therapies [82]. Figure 7 
shows examples of cross-sectional OCT images and corresponding histology. Figures 7A and 7B were 
acquired in vivo at the position of the GEJ. SSIM was identified with 3D-OCT at the GEJ of a patient 
during the imaging procedure. The corresponding histological micrograph shown in Figure 7C 
confirmed the presence of SSIM with intestinal metaplasia underneath the neosquamous epithelium. 
Figures 7D and 7E were obtained from an ex vivo EMR specimen to enable more accurate correspondence 
of OCT images with histology. From cross-sectional OCT images, squamous epithelium was 
characterized by a low scattering, homogeneous layer at the mucosal surface. SSIM was identified as 
sparsely distributed hyposcattering structures underneath the squamous epithelium with various sizes 
and shapes. The histological micrograph of the EMR specimen (Figure 7F) also confirmed the 
presence of buried glands with intestinal metaplasia. 
Figure 7. Cross-sectional optical coherence tomography images and corresponding 
histology showing buried glands (red arrowheads) from a patient in vivo (A–C) and an  
ex vivo EMR specimen (D–F). (C,F) Histological micrographs confirmed the presence of 
buried glands with intestinal metaplasia. SE: squamous epithelium. Scale bars, 500 µm. 
Originally published in [155]. 
 
In the study of 27 patients with short-segment BE, 3D-OCT was demonstrated to provide a 30–60 
times larger field of view compared with jumbo and standard forceps biopsy and sufficient imaging 
depth to the lamina propria/muscularis mucosa to facilitate the detection of SSIM before and after the 
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treatment [155]. A high prevalence of SSIM was found in 72% of patients who had residual BE and in 
63% of patients who achieved complete response to the ablation treatment. The high prevalence is 
consistent with biopsy results from previous studies when accounting for difference in sampling area 
between OCT imaging and excisional biopsy [156]. The number of SSIM per patient decreased 
significantly after the patients achieved complete response (p = 0.02). However, the size and 
distribution of the SSIM did not change significantly in patients with short-segment BE whether the 
patients achieved complete response or not. This study suggested that OCT may be used to stratify the 
patient risk and could help direct areas for re-ablation. 
4.4. RFA Treatment Response Evaluation 
Repeated RFA treatments are generally required to achieve complete eradication of intestinal 
metaplasia. Complete eradication of intestinal metaplasia (CE-IM) was achieved over three sessions on 
average for patients with BE [53,64,157]. The long overall treatment period plus the cost to achieve 
complete eradication mounts with each esophagogastroduodenoscopy (EGD) and RFA procedure, 
which has tempered the enthusiasm to treat patients with non-dysplastic BE (NDBE) using RFA [64]. 
There are various causes that may contribute to incompleteness of the ablation. Since the dosage of the 
RFA treatment has been set to achieve best efficacy with minimum injury depth [158,159], the energy 
delivery of a standard RFA application might not reach deep enough when the BE epithelium is thick. 
The variation of the RFA electrode contact with the esophagus and coagulated debris building up on 
the electrode surface during repeated ablation in one patient also can degrade the effectiveness of the 
radiofrequency energy delivery [159]. Therefore, tissue structural features, including SSIM, the BE 
epithelium thickness, and residual glands that receive insufficient ablation or no ablation, can 
potentially be used to predict or evaluate the ablation treatment response. It is difficult to evaluate the 
presence of residual glands or unburned BE by using white light endoscopy or narrow-band imaging 
because of the limited visibility immediately after the RFA treatment, when the endoscopic imaging 
field is covered with blood and tissue debris. Traditional evaluation of treatment response is usually 
performed after 6–8 weeks allowing the recovery of the ablated regions, so the entire treatment process 
can easily span half a year or longer if multiple RFA sessions are required. 
In the study of 33 patients with short-segment BE, 3D-OCT identified structural markers, including 
the thickness of the BE epithelium prior to RFA and the presence of residual glands immediately after 
RFA, which might be used to predict RFA treatment response at follow-up with high accuracy [160].  
It was found that BE thick varied widely, from 200 to 700 µm in this cohort of patients, and OCT 
measurement of BE thickness of >330 µm predicted incomplete treatment response at follow-up visit 
6–8 weeks after the RFA treatment with a sensitivity and specificity of 92% and 85%, respectively 
(Figure 8A,B). This raises the possibility that energy delivery of a standard RFA application may not 
be reaching deep enough when the BE epithelium is thick. In this study, a co rrelation was found 
between the BE epithelium thickness and the presence of residual glands immediately after RFA, 
suggesting not all RFA applications were effective. Insufficient energy delivery at the treatment sites 
or leaving BE unburned may be factors that lead to endoscopically visible residual BE at follow-up. 
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Figure 8. (A) Scatter plot of the average BE epithelium thickness measured by OCT from 
different patient groups. Blue circles: patients who did not achieve CE-IM at the follow-up 
sessions; Red crosses: patients who achieved CE-IM at the follow-up sessions; Green 
dotted line: discrimination threshold at 333 µm as d etermined from the average BE 
thickness ROC curve in (B). (B) ROC curves of treatment response prediction using 
average (green) and maximum (blue) BE thickness. The area-under-the-curve (AUC) 
values were 0.942 (p < 0.001) and 0.934 (p < 0.001) using the average and maximum BE 
thickness, respectively. Originally published in [160]. 
 
The efficacy of ablation therapies is assessed by follow-up endoscopy 6–8 weeks after RFA, and 
patients undergo repeated ablation if residual BE is observed. These results suggest that patient complete 
response rate may be stratified based on the BE thickness measured before RFA. Using this structural 
marker, it may be possible to adjust RFA treatment for each patient to optimize response. For patients 
with thicker BE epithelium, a more rigorous ablation may be required. This may involve a removing 
debris from the ablation catheter and treatment areas between the two sets of ablations, and if indicated, 
changed dosage for the RFA treatment. The ability of OCT to differentiate residual glands from normal 
tissue structures and debris caused by the ablation may also provide immediate feedback on the RFA 
treatment for the endoscopist. This may enable “smart ablation” mechanism that real-time evaluates 
the ablation depth and identifies regions requiring further treatment. The RFA treatment might be 
guided to further improve the efficacy of each ablation procedure. As a result, the number of treatment 
sessions might be reduced to reduce overall treatment time, patient anxiety and health care cost. 
4.5. Investigation of Cervical Inlet Patch 
Cervical inlet patch (CIP) is characterized by the presence of heterotopic columnar gastric mucosa 
in the upper esophagus, most commonly located just below the upper esophageal sphincter (UES). The 
incident of CIP has been reported from as l ow as 1 % to as m uch as 10% of endoscopic cases in 
different adult studies [161,162], but is under-appreciated given its location generally just below the 
upper esophageal sphincter, which remains an area of poor detection during routine upper endoscopy. 
It is unclear whether CIP is congenital or acquired. One postulate is that CIP originates from 
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incomplete embryonic replacement of the stratified epithelium, which normally starts at the fourth 
month of gestation. Immunohistochemical studies suggest an embryologic origin for CIP on account of 
differences in endocrine markers such as serotonin, glucagon, pancreatic polypeptide, somatostatin and 
neurotensin in histologic specimens of CIP and BE [163]. A second postulate is that CIP, especially as 
noted in adults, is an acquired metaplastic change occurring in the squamous mucosa of the esophagus 
and is associated with predisposing factors for gastroesophageal reflux disease (GERD), such as 
sliding hiatal hernia [164]. Its incidence is up to four-fold higher in patients having BE [165] and CIP 
was found in almost one third of patients having dysplastic BE or adenocarcinoma [166]. Thus,  
long-standing acid reflux is thought to lead to columnar metaplasia in the upper esophagus, similar to 
BE. Several reports suggest that CIP may progress to adenocarcinoma [167–170]. 
Figure 9 shows an endoscopic view of and volumetric 3D-OCT data set of CIP obtained from a  
30-year-old patient [171,172]. During retraction of the endoscope, a pink circular lesion was observed 
under white light endoscopy in the upper esophagus (Figure 9A). The en face projection image  
(Figure 9B) at 400 µm depth underneath the tissue surface showed columnar epithelium consistent 
with the CIP and surrounding squamous epithelium. Cross-sectional OCT images (Figures 9C, 9D, and 
9F) clearly demonstrated columnar and squamous epithelium in the CIP region and the surrounding 
esophagus, respectively. Biopsy specimens taken from the imaged lesion confirmed the finding of CIP. 
The OCT features matched representative hematoxylin and eosin (H&E) histology (Figures 9E  
and 9G). These results demonstrated the feasibility of using OCT to evaluate GI tissue morphology  
in situ and in real-time [171,172]. Since OCT imaging can be performed with small diameter catheters 
introduced orally or nasally, this emerging technology might be used to screen patients with 
troublesome upper esophagus symptom for CIP, BE and other changes in the epithelium, in an 
outpatient clinic without endoscopy or the need for conscious sedation. 
Figure 9. Cervical inlet patch (CIP). (A) Endoscopic view. (B) En face projection OCT 
image at 400 µm underneath the tissue surface. Regions with CIP and surrounding 
squamous epithelium (SE) can be identified. (C) Cross-sectional OCT image along  
the probe pullback direction, corresponding to the red dashed line marked in (B).  
(D,F) Cross-sectional OCT images of squamous epithelium and CIP, respectively. The 
OCT images correspond to the blue and green dashed lines marked in (B), respectively. 
(E,G) Representative histology of normal squamous epithelium and CIP. Scale bars: 1mm. 
Originally published in [171]. 
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4.6. Diagnostic Accuracy Using Endoscopic OCT Imaging  
Although early detection of Barrett’s metaplasia could decrease morbidity and mortality, the present 
gold standard to diagnose BE relies upon both endoscopic visualization and histopathologic findings, 
which are costly and fraught with limited sampling error, as discussed in Section 4.1. The  
well-accepted Prague classification could guide endoscopic recognition of BE to improve diagnostic 
yield of biopsies for potential BE [173], but esophagitis which can often be present may confound both 
endoscopic and histological identification of BE [174,175]. Endoscopic OCT is able to produce  
high-resolution volumetric imaging of the entire distal esophagus, and thus would have much lower 
sampling error compared to standard pinch biopsies for BE. Sauk et al. performed a clinical study 
demonstrating that gastroenterologists with limited OCT experience are able to be trained to diagnose 
intestinal metaplasia simply based on OCT images of the distal esophagus [176]. This study evaluated 
the inter-observer agreement of 10 readers in diagnosing BE from OCT images. Six of the readers 
participating in the study including a pathologist had no prior formal training in esophageal OCT 
image interpretation, while the other readers had extensive experience with OCT technology. All were 
given a training set and subsequently interpreted a test set. Inter-observer agreement for differentiating 
mucosa in esophagus versus stomach, and BE versus non-BE mucosa was determined using multi-rater 
Fleiss’s κ value which was used to assess the agreement across the readers. Forty-five data sets were 
included in the test set and all 10 readers had excellent agreement for the OCT differentiation of 
intestinal metaplasia versus non-BE with a κ value of 0.811. For the six readers with limited OCT 
experience and no formal training, a good agreement was achieved with a κ value of 0.765, while the 
experienced four readers demonstrated excellent agreement with a κ value of 0.872. They reported that 
heterogeneous backscatter and irregular surface morphology were the features of BE that most 
frequently drove the correct diagnosis [169]. This preliminary study concluded that a large group of 
readers, including both endoscopists and non-endoscopists, would be able to interpret OCT images 
after being trained and achieve an excellent inter-observer agreement. It is noted that OCT provides 
full circumferential views of the distal esophagus with micron-level resolution in 2 min, which is much 
faster than the standard of care requiring endoscopy with biopsies. However, as a potential screening 
tool, this study did not include pathologic diagnosis as the gold standard in the test due to the lack of 
registration between the biopsy sites and the OCT imaged sites. Moreover, as a potential surveillance 
tool, perhaps the more difficult distinction between dysplasia and inflammation or cancer in the setting 
of BE was not addressed. Therefore, the results reported in this study do not represent the diagnostic 
accuracy of OCT with respect to histology and will require validation in future histopathologic 
correlative studies using the laser marking technology mentioned in Section 4.1 [83]. Nonetheless, 
these preliminary findings suggest that endoscopic OCT can potentially be a promising tool for  
low-cost screening and surveillance of the distal esophagus. 
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5. Future Applications 
Besides the above mentioned clinical research, there are other case studies reporting the use of 
endoscopic OCT imaging in the GI tract, including ectatic vessels of chronic radiation proctitis (CRP) 
pre- and post-RFA treatment [88,177], and comparative tissue architectural changes between RFA and 
CSA [178]. Moreover, several new endoscopic imaging catheter designs have been reported that 
enhance the visualization of the GI tract [144,146,179,180]. Recently, the first commercialized OCT 
imaging system specifically for the upper GI tract was developed by NinePoint Medical, Inc. 
(Cambridge, MA, USA) and has been used in multiple ongoing clinical trials worldwide, also 
indicating the broad acceptance of endoscopic OCT for clinical applications. Since each imaging 
technology has its advantages and disadvantages, the development of integrated platforms that 
combine OCT with other endoscopic imaging modalities can potentially overcome the limitations of 
individual modalities [138]. For example, endoscopic OCT is capable of visualizing micrometer-scale 
tissue structural morphologies with intrinsic tissue contrast, and CLE provides sub-micrometer-scale, 
cellular-level images with endogenous or exogenous contrast. These two complementary imaging 
modalities can provide important yet different optical information based on uni que contrast 
mechanisms. Moreover, the combination of endoscopic OCT with nanotechnology can potentially 
introduce new clinical applications including enhanced cancer diagnosis and targeted cancer therapy. 
The diagnosis and imaging of cancer may be pursued by the intravenous injection and selective 
accumulation of nanoparticles inside the malignant cells, either passively through the enhanced 
permeation and retention of solid tumors, or actively in conjunction with antibodies, aptamers, and 
peptides [181,182]. By generating localized thermal modulation induced by photothermal excitation of 
the nanoparticles, the phase variation at the targeted regions can be detected using phase-sensitive 
OCT [183]. The nanoparticles could also be used to induce the apoptosis of the malignant cells by 
photothermal or photoacoustic microsurgery as well as by t he association of cytotoxic drugs [181], 
which can achieve the targeted cancer treatment. Further improvements in the catheter design and  
data acquisition technology will allow volumetric imaging with enhanced microscopic resolution and  
ease of integration with multiple imaging modalities and should enable a w ide range of clinical  
endoscopy applications. 
6. Conclusions 
While endoscopic OCT does not possess the same magnification or contrast as conventional 
histopathology, it provides unique imaging capability that can visualize tissue microstructure in vivo 
over a large field of view and provides real-time, depth-resolved information with micron scale 
resolution. With recent advances in swept source and high speed data acquisition technology,  
ultrahigh speed OCT imaging can be achieved that allows visualization of the tissue dynamic  
or 3D tissue structure in a short time [146]. In conjunction with standard white light endoscopy, studies 
have demonstrated the clinical utility of endoscopic OCT for gastroenterology, which includes 
minimally invasive imaging and optical biopsy without the use of exogenous contrast, volumetric 
imaging with improved diagnostic yield, and real-time imaging for immediate post-treatment 
assessment [83,151,155,160,171,172,176,178]. These features make endoscopic OCT particularly 
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suited for detecting small lesions, which can be easily missed if relying on limited random biopsy 
sampling and on subsequent limited sectioning of the biopsies for pathological inspection. OCT can 
also discern lesions under the luminal surface. Future efforts are still required to make the most of the 
endoscopic OCT. With high imaging speed, volumetric OCT data sets with frame-by-frame registration 
can reveal detailed tissue structure with minimized distortion due to motion or scanning artifacts, so 
advanced image processing techniques can be used to extract the volumetric information more 
efficiently. Segmentation techniques can be applied to separate different tissue layers in the squamous 
mucosa or BE mucosa, and structural features such as thickness of BE epithelium can be automatically 
quantified immediately after the acquisition of volumetric data set. Pattern recognition techniques can 
be applied on both cross-sectional and en face images to detect other structural features including 
SSIM, residual/untreated glandular structure immediately after the treatment, and pit patterns of crypts 
in colon or BE. The development of such techniques will benefit the treatment management by availing 
structural information immediately to the clinician for appropriate treatment options and dosages to 
optimize treatment outcomes. Studies of endoscopic OCT for pre- and post-therapy analysis can be 
conducted with long term follow-up of patients treated with RFA, CSA, endoscopic mucosal resection, 
photodynamic therapy, argon plasma coagulation, or other emerging endoscopic treatments. Endoscopic 
OCT could also be studied as an intra-therapy tool for guiding the dosage or resection depth of these 
therapeutic techniques. Studies in endoscopic OCT screening for dysplasia in the setting of BE or 
inflammatory bowel disease could also be revisited with improvements in fields of view, resolution, 
and reliability of 3D information. Long-term clinical studies are needed to decisively establish the 
clinical utility of endoscopic OCT imaging for broad use beyond the specialty research centers. 
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